Ixekizumab for COVID-19: real-time analysis

Download Image

Post

c19early.org

Ixekizumab for COVID-19

1 study with 32 patients

Serious outcome risk

Ixekizumab

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 Ixekizumab studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−50%

Mortality (1)−50%

RCTs (1)−50%

Late (1)−50%

00.511.5+

← Ixekizumab
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


Apr 28 2022	Pimenta Bonifácio et al., Revista da Sociedade Brasileira de Medicina Tropical, doi:10.1590/0037-8682-0565-2022 (date from preprint)	Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors)
Apr 28 2022	50% higher mortality (p=1) and no change in improvement (p=1). Open label RCT late stage hospitalized patients in Brazil showing no significant difference with IL-2 or ixekizumab treatment. Mortality was lower and recovery was greater with colchicine, without statistical significance.